SCHEMBL12876134

SCHEMBL12876134

CCOC(=O)c1cnn(Cc2nc(-c3cc(C)cc(OCc4ccc(F)cc4F)c3)cs2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.41
ALKBH1 Q13686 2/20 0.41
KDM4E B2RXH2 4/20 0.38
HPGD P15428 4/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
KLKB1 P03952 2/20 0.38
MAOB P27338 1/20 0.37
MAPT P10636 5/20 0.37
L3MBTL1 Q9Y468 5/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
GAA P10253 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876136 0.92 ALKBH1 (0.50) ALKBH1KLKB1MAOBL3MBTL1NPC1
SCHEMBL1199018 0.91 ALDH1A1 (0.41) GRM2ALKBH1KDM4EHPGDALDH1A1
SCHEMBL12875801 0.84 GRM2 (0.45) GRM2KDM4EHPGDALDH1A1CYP1A2
SCHEMBL12876016 0.83 MEN1 (0.39) GRM2KDM4EHPGDALDH1A1CYP1A2
SCHEMBL12876120 0.82 MMP13 (0.46) GRM2ALDH1A1KLKB1MAPTL3MBTL1
SCHEMBL1198853 0.82 KDM4E (0.52) GRM2KDM4EHPGDALDH1A1CYP1A2
SCHEMBL12876118 0.81 GRM2 (0.40) GRM2KDM4EHPGDALDH1A1CYP1A2
SCHEMBL1197965 0.81 ALKBH1 (0.49) ALKBH1KDM4EALDH1A1KLKB1MAOB
SCHEMBL2861439 0.80 ALKBH1 (0.51) ALKBH1MAOB
SCHEMBL12875991 0.80 MAPT (0.49) GRM2ALKBH1KDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A GRM2 1900/4885ALKBH1 1916/4885KDM4E 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.